TBPH FY 2023 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$716M

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$57M+11.8% YoY

Gross Profit

$17M29.3% margin

Operating Income

-$56M-97.6% margin

Net Income

-$55M-96.1% margin

EPS (Diluted)

$-1.00

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$29M

Stock-Based Comp.

$25M

Balance Sheet

Total Assets

$382M

Total Liabilities

$169M

Stockholders' Equity

$213M

Cash & Equivalents

$40M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$57M	$51M	+11.8%
Gross Profit	$17M	-$12M	+239.5%
Operating Income	-$56M	-$92M	+39.1%
Net Income	-$55M	$872M	-106.3%